ArticlePharmacoEconomics2022

Cost Effectiveness of the First-in-Class ARNI (Sacubitril/Valsartan) for the Treatment of Essential Hypertension in a Chinese Setting.

Xinyue Dong et al.PubMed ↗Publisher ↗

No numbers read from the abstract.